Natera enrolls first patients in Signatera-guided melanoma study
Natera said it enrolled the first patients in a randomized Signatera-guided interventional trial in melanoma sponsored by NYU Langone Health (NCT07504796).
Story updates
12:01:08 PM UTC
SquawkNews
Natera began enrollment in a randomized NYU Langone—sponsored melanoma study using Signatera to guide therapy escalation based on MRD after six weeks of first-line treatment. The primary endpoint is progression-free survival.Material DetailsContext by AI AnalystThis is an early-stage clinical utili…